OUTLOOK THERAPEUTICS INC (OTLK NASDAQ) stock market data APIs
$0.4267
-0.02(-4.7%)
as of February 6, 2026
Try our APIs with
free plan!
OUTLOOK THERAPEUTICS INC Financial Data Overview
Price chart is built with
Anychart
Outlook Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic bevacizumab product formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration agreements with Cencora. Outlook Therapeutics, Inc. was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in November 2018. Outlook Therapeutics, Inc. was incorporated in 2010 and is based in Iselin, New Jersey.
Prev. Close
0.4267
Open
0.4025
High
0.4469
Low
0.3789
52 wk Range
0.3801-3.39
Market Cap
28 669 K
Shares Outstanding
73 509 K
Revenue
1 414 K
EPS
-0.28
Beta
-0.067
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with OUTLOOK THERAPEUTICS INC (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get OUTLOOK THERAPEUTICS INC data using free add-ons & libraries
Get OUTLOOK THERAPEUTICS INC Fundamental Data
OUTLOOK THERAPEUTICS INC Fundamental data includes:
- Net Revenue: 1 414 K
- EBITDA: -66 944 616
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-12-19
- EPS/Forecast: -0.06
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
OUTLOOK THERAPEUTICS INC News
New
OTLK Stock Crashes 67% in a Week: Here's What You Need to Know
Shares of Outlook Therapeutics OTLK have tumbled 66.5% in a week. The massive crash was observed after the FDA issued a third complete response letter (CRL) in late December, rejecting OTLK’s biolog...
Sector Update: Health Care Stocks Advance Late Afternoon
Health care stocks rose late Friday afternoon, with the NYSE Health Care Index adding 0.5% and the S PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscri...
Baidu, ASML, furniture stocks rise; Outlook Therapeutics sinks
Investing.com -- U.S. futures are trading higher with Nasdaq 100 Futures futures up as much as 1.1% in pre-market Friday. ASML (NASDAQ:ASML) are up 4.9% after Aletheia Capital double-upgraded the Eur...
Weekly Buzz: ARS Pharma's Neffy Goes East, SLS Advances, A Signal Of Hope For IFRX?
(RTTNews) - Despite the typical year-end slowdown, the week saw a steady stream of high-impact news, highlighted by global approvals, clinical trial readouts, new product launches, and strategic buyou...
Get OUTLOOK THERAPEUTICS INC fresh news feed via Financial News API
$19.99/mo.
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
